Journal of Cardiac Failure
Volume 15, Issue 10 , Pages 819-827, December 2009

Resource Use and Costs of Treatment With Anticoagulation and Antiplatelet Agents: Results of the WATCH Trial Economic Evaluation

  • Mark E. Patterson, PhD, MPH

      Affiliations

    • Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina
    • ,
  • William C. Grant, PhD

      Affiliations

    • Department of Economics, James Madison University, Harrisonburg, Virginia
    • ,
  • Seth W. Glickman, MD, MBA

      Affiliations

    • Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina
    • ,
  • Barry M. Massie, MD

      Affiliations

    • San Francisco Veterans Affairs Medical Center and University of California, San Francisco
    • ,
  • Susan E. Ammon, MS, RN, FNP

      Affiliations

    • San Francisco Veterans Affairs Medical Center and University of California, San Francisco
    • ,
  • Paul W. Armstrong, MD

      Affiliations

    • University of Alberta, Edmonton
    • ,
  • John G.F. Cleland, MD

      Affiliations

    • Department of Cardiology, Castle Hill Hospital, University of Hull, Kingston-Upon-Hull, United Kingdom
    • ,
  • Joseph F. Collins, SCD

      Affiliations

    • Cooperative Studies Program Coordinating Center, VA Maryland Health Care System, Perry Point, Maryland
    • ,
  • Koon K. Teo, MBBCH, PhD

      Affiliations

    • McMaster University Medical Center, Hamilton, Ontario
    • ,
  • Kevin A. Schulman, MD

      Affiliations

    • Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina
    • ,
  • Shelby D. Reed, PhD

      Affiliations

    • Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina
    • Corresponding Author InformationReprint requests: Shelby D. Reed, PhD, Center for Clinical Genetics and Economics, Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715. Tel: (919) 668-8101; Fax: (919) 668-7124

Received 7 July 2008; received in revised form 1 May 2009; accepted 1 July 2009. published online 24 August 2009.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 All decisions regarding this manuscript were made by a guest editor.

 The WATCH trial was conducted under the auspices of the US Department of Veterans Affairs Cooperative Study Program, with partial unrestricted support from Bristol-Myers Squibb Company and Sanofi-Aventis.

PII: S1071-9164(09)00681-2

doi:10.1016/j.cardfail.2009.07.004

Journal of Cardiac Failure
Volume 15, Issue 10 , Pages 819-827, December 2009

Article Tools